{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:12:11Z","timestamp":1753877531209,"version":"3.41.2"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T00:00:00Z","timestamp":1649548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000140","name":"U.S. Department of Transportation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000140","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008760","name":"National Highway Traffic Safety Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008760","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bloomberg American Health Initiative COVID-19 Impact grant"},{"name":"Johns Hopkins University Catalyst Award"},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["U54EB007958-13","U54EB007958-12S1"],"award-info":[{"award-number":["U54EB007958-13","U54EB007958-12S1"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Population-based seroprevalence studies offer comprehensive characterization of coronavirus disease 2019 (COVID-19) spread, but barriers exist and marginalized populations may not be captured. We assessed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody seroprevalence among decedents in Maryland over 6 months in 2020.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were collected on decedents undergoing forensic postmortem examination in Maryland from 24 May through 30 November 2020 from whom a blood specimen could be collected. Those with available blood specimens were tested with the CoronaCHEK lateral flow antibody assay. We assessed monthly seroprevalence compared to the statewide estimated number of cases and proportion of positive test results (testing positivity). We used Poisson regression with robust variance to estimate adjusted prevalence ratios (aPRs) with 95% confidence intervals (CIs) for associations of demographic characteristics, homelessness, and manner of death with SARS-CoV-2 antibodies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 1906 decedents, 305 (16%) were positive for SARS-CoV-2 antibodies. Monthly seroprevalence increased from 11% to 22% over time and was consistently higher than state-level estimates of testing positivity. Hispanic ethnicity was associated with 2- to 3.2-fold higher seropositivity (P\u2005&amp;lt;\u2005.05) irrespective of sex. Deaths due to motor vehicle crash were associated with 62% increased seropositivity (aPR, 1.62 [95% CI, 1.15\u20132.28]) vs natural manner of death. Though seroprevalence was lower in decedents of illicit drug overdose vs nonoverdose in early months, this shifted, and seroprevalence was comparable by November 2020.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Decedents undergoing forensic postmortem examination, especially those dying due to motor vehicle trauma, may be a sentinel population for COVID-19 spread in the general population and merits exploration in other states\/regions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofac142","type":"journal-article","created":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T16:28:20Z","timestamp":1649608100000},"source":"Crossref","is-referenced-by-count":0,"title":["Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in Decedents Undergoing Forensic Postmortem Examination: Feasibility for &amp;#x2028;Real-Time Pandemic Surveillance"],"prefix":"10.1093","volume":"9","author":[{"given":"Sally B","family":"Coburn","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari C","family":"Manabe","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Laeyendecker","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA"},{"name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan G","family":"Sherman","sequence":"additional","affiliation":[{"name":"Department of Health, Behavior, and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen R","family":"Baker","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C","family":"Quinn","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA"},{"name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey A","family":"Graham","sequence":"additional","affiliation":[{"name":"Dunlap and Associates, Inc, Stamford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Dennis\u00a0Thomas","sequence":"additional","affiliation":[{"name":"Dunlap and Associates, Inc, Stamford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Southall","sequence":"additional","affiliation":[{"name":"Office of the Chief Medical Examiner, Maryland Department of Health, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor W","family":"Weedn","sequence":"additional","affiliation":[{"name":"University of Maryland Baltimore Graduate School, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnathon","family":"Ehsani","sequence":"additional","affiliation":[{"name":"Center for Injury Research and Policy, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan","family":"Klock","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[{"name":"Office of the Chief Medical Examiner, Maryland Department of Health, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy C","family":"Shields","sequence":"additional","affiliation":[{"name":"Center for Injury Research and Policy, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey Paul","family":"Michael","sequence":"additional","affiliation":[{"name":"Center for Injury Research and Policy, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[{"name":"Office of the Chief Medical Examiner, Maryland Department of Health, Baltimore, Maryland, USA"},{"name":"Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keri\u00a0N","family":"Althoff","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,4,10]]},"reference":[{"key":"2022041016280900400_CIT0001","doi-asserted-by":"crossref","first-page":"15761776","DOI":"10.1001\/jamainternmed.2020.4130","article-title":"Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23\u2013May 12, 2020.","volume":"180","author":"Havers","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2022041016280900400_CIT0002","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jamainternmed.2020.7976","article-title":"Estimated SARS-CoV-2 seroprevalence in the US as of September 2020.","volume":"181","author":"Bajema","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2022041016280900400_CIT0003"},{"key":"2022041016280900400_CIT0004","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M20-3012","article-title":"Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review.","volume":"173","author":"Oran","year":"2020","journal-title":"Ann Intern Med"},{"key":"2022041016280900400_CIT0005","doi-asserted-by":"crossref","first-page":"e2021213","DOI":"10.1001\/jamanetworkopen.2020.21213","article-title":"Assessment of disparities in COVID-19 testing and infection across language groups in Seattle, Washington.","volume":"3","author":"Duber","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2022041016280900400_CIT0006","doi-asserted-by":"crossref","DOI":"10.1111\/hsc.13621","article-title":"COVID-19 diagnostic testing among underserved Latino communities: barriers and facilitators [manuscript published online ahead of print 31 October 2021].","author":"Garcini","year":"2021","journal-title":"Health Soc Care Community"},{"key":"2022041016280900400_CIT0007","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/ije\/dyab010","article-title":"COVID-19 antibody seroprevalence in Santa Clara County, California.","volume":"50","author":"Bendavid","year":"2021","journal-title":"Int J Epidemiol"},{"key":"2022041016280900400_CIT0008","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/infdis\/jiaa429","article-title":"Estimation without representation: early severe acute respiratory syndrome coronavirus 2 seroprevalence studies and the path forward.","volume":"222","author":"Shook-Sa","year":"2020","journal-title":"J Infect Dis"},{"key":"2022041016280900400_CIT0009","doi-asserted-by":"crossref","first-page":"960","DOI":"10.15585\/mmwr.mm6929e1","article-title":"Population point prevalence of SARS-CoV-2 infection based on a statewide random sample\u2014Indiana, April 25\u201329, 2020.","volume":"69","author":"Menachemi","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022041016280900400_CIT0010","doi-asserted-by":"crossref","first-page":"965","DOI":"10.15585\/mmwr.mm6929e2","article-title":"Estimated community seroprevalence of SARS-CoV-2 antibodies\u2014two Georgia counties, April 28\u2013May 3, 2020.","volume":"69","author":"Biggs","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022041016280900400_CIT0011","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/infdis\/jiab522","article-title":"Cumulative incidence of SARS-CoV-2 infections among adults in Georgia, United States, August to December 2020.","volume":"225","author":"Chamberlain","year":"2022","journal-title":"J Infect Dis"},{"key":"2022041016280900400_CIT0012","first-page":"ofaa611","article-title":"Severe acute respiratory syndrome coronavirus 2 antibody status in decedents undergoing forensic postmortem examination in Maryland, May 24 to June 30, 2020.","volume-title":"Open Forum Infect Dis","author":"Althoff","year":"2020"},{"key":"2022041016280900400_CIT0013","article-title":"Rapid real-time tracking of non-pharmaceutical interventions and their association SARS-CoV-2 positivity: the COVID-19 Pandemic Pulse Study.","author":"Clipman","year":"2020","journal-title":"medRxiv"},{"key":"2022041016280900400_CIT0014","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/jama.2020.11374","article-title":"SARS-CoV-2 positivity rate for Latinos in the Baltimore\u2013Washington, DC region.","volume":"324","author":"Martinez","year":"2020","journal-title":"JAMA"},{"key":"2022041016280900400_CIT0015","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/jamapsychiatry.2020.4402","article-title":"Trends in US emergency department visits for mental health, overdose, and violence outcomes \u00adbefore and during the COVID-19 pandemic.","volume":"78","author":"Holland","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"2022041016280900400_CIT0016","doi-asserted-by":"crossref","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and geographic patterns in drug and synthetic opioid overdose deaths\u2014United States, 2013\u20132019.","volume":"70","author":"Mattson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"volume-title":"Drug overdose deaths in the United States, 1999\u20132019","year":"2020","author":"Hedegaard","key":"2022041016280900400_CIT0017"},{"key":"2022041016280900400_CIT0018","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1093\/cid\/ciab373","article-title":"Changes in emergency medical services before and during the COVID-19 pandemic in the United States, January 2018\u2013December 2020.","volume":"73","author":"Handberry","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022041016280900400_CIT0019","doi-asserted-by":"crossref","first-page":"e02020-20","DOI":"10.1128\/JCM.02020-20","article-title":"Evaluation of serological SARS-CoV-2 lateral flow assays for rapid point-of-care testing.","volume":"59","author":"Conklin","year":"2021","journal-title":"J Clin Microbiol"},{"key":"2022041016280900400_CIT0020","doi-asserted-by":"crossref","first-page":"e0083721","DOI":"10.1128\/JCM.00837-21","article-title":"Differential performance of CoronaCHEK SARS-CoV-2 lateral flow antibody assay by geographic origin of samples.","volume":"59","author":"Baker","year":"2021","journal-title":"J Clin Microbiol"},{"key":"2022041016280900400_CIT0021","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3390\/diagnostics10050319","article-title":"Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis.","volume":"10","author":"Kontou","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"2022041016280900400_CIT0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-82428-5","article-title":"Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan.","volume":"11","author":"Nakano","year":"2021","journal-title":"Sci Rep"},{"key":"2022041016280900400_CIT0023","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time.","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2022041016280900400_CIT0024","doi-asserted-by":"crossref","first-page":"e211552","DOI":"10.1001\/jamanetworkopen.2021.1552","article-title":"Seroprevalence of SARS-CoV-2 antibodies in the US adult asymptomatic population as of September 30, 2020.","volume":"4","author":"Stout","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2022041016280900400_CIT0025","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/jama.2021.15161","article-title":"Estimated US infection- and vaccine-induced SARS-CoV-2 seroprevalence based on blood donations, July 2020\u2013May 2021.","volume":"326","author":"Jones","year":"2021","journal-title":"JAMA"},{"key":"2022041016280900400_CIT0026","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M20-6306","article-title":"Racial and ethnic disparities in covid-19-related infections, hospitalizations, and deaths a systematic review.","volume":"174","author":"Mackey","year":"2021","journal-title":"Ann Intern Med"},{"key":"2022041016280900400_CIT0027","doi-asserted-by":"crossref","first-page":"e2034578","DOI":"10.1001\/jamanetworkopen.2020.34578","article-title":"Association of social and economic inequality with coronavirus disease 2019 incidence and mortality across US counties.","volume":"4","author":"Liao","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2022041016280900400_CIT0028","doi-asserted-by":"crossref","first-page":"e2016938","DOI":"10.1001\/jamanetworkopen.2020.16938","article-title":"Assessment of community-level disparities in coronavirus disease 2019 (COVID-19) infections and deaths in large US metropolitan areas.","volume":"3","author":"Adhikari","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2022041016280900400_CIT0029","doi-asserted-by":"crossref","first-page":"e2036462","DOI":"10.1001\/jamanetworkopen.2020.36462","article-title":"Association of social and demographic factors with COVID-19 incidence and death rates in the US.","volume":"4","author":"Karmakar","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2022041016280900400_CIT0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/13557858.2020.1853067","article-title":"Racial, ethnic, and socioeconomic disparities in confirmed COVID-19 cases and deaths in the United States: a county-level analysis as of November 2020.","volume":"26","author":"Khanijahani","year":"2021","journal-title":"Ethn Health"},{"key":"2022041016280900400_CIT0031","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/PHH.0000000000001354","article-title":"Population-level disparities in COVID-19: measuring the independent association of the proportion of black population on COVID-19 cases and deaths in US counties.","volume":"27","author":"Gaglioti","year":"2021","journal-title":"J Public Heal Manag Pract"},{"key":"2022041016280900400_CIT0032","doi-asserted-by":"crossref","first-page":"e218799","DOI":"10.1001\/jamanetworkopen.2021.8799","article-title":"Association between income inequality and county-level COVID-19 cases and deaths in the US.","volume":"4","author":"Tan","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2022041016280900400_CIT0033","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3961\/jpmph.21.126","article-title":"Association of lower socioeconomic status and SARS-CoV-2 positivity in Los Angeles, California.","volume":"54","author":"Allan-Blitz","year":"2021","journal-title":"J Prev Med Public Health"},{"key":"2022041016280900400_CIT0034","doi-asserted-by":"crossref","first-page":"e039849","DOI":"10.1136\/bmjopen-2020-039849","article-title":"Racial and ethnic disparities in SARS-CoV-2 pandemic: analysis of a COVID-19 observational registry for a diverse US metropolitan population.","volume":"10","author":"Vahidy","year":"2020","journal-title":"BMJ Open"},{"key":"2022041016280900400_CIT0035","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.15585\/mmwr.mm6933e1","article-title":"Disparities in incidence of COVID-19 among underrepresented racial\/ethnic groups in counties identified as hotspots during June 5\u201318, 2020\u201422 states, February\u2013June 2020.","volume":"69","author":"Moore","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022041016280900400_CIT0036","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.puhe.2020.09.016","article-title":"Socio-economic status and COVID-19\u2013related cases and fatalities.","volume":"189","author":"Hawkins","year":"2020","journal-title":"Public Health"},{"key":"2022041016280900400_CIT0037","doi-asserted-by":"crossref","first-page":"108321","DOI":"10.1016\/j.drugalcdep.2020.108321","article-title":"Opioid-related\u00a0\u00adoverdose mortality in the era of fentanyl: monitoring a shifting \u00adepidemic\u00a0by\u00a0person, place, and time.","volume":"216","author":"Althoff","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"2022041016280900400_CIT0038","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/EDE.0000000000000858","article-title":"Trends in black and white opioid mortality in the United States, 1979\u20132015.","volume":"29","author":"Alexander","year":"2018","journal-title":"Epidemiology"},{"key":"2022041016280900400_CIT0039","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/aje\/kwv099","article-title":"Trends in socioeconomic inequalities in motor vehicle accident deaths in the United States, 1995\u20132010.","volume":"182","author":"Harper","year":"2015","journal-title":"Am J Epidemiol"},{"key":"2022041016280900400_CIT0040","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0001-4575(01)00106-3","article-title":"Race, Hispanic origin, and socioeconomic status in relation to motor vehicle occupant death rates and risk factors among adults.","volume":"35","author":"Braver","year":"2003","journal-title":"Accid Anal Prev"},{"key":"2022041016280900400_CIT0041","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13011-021-00423-5","article-title":"The impact of the novel coronavirus disease (COVID-19) pandemic on drug overdose-related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data.","volume":"16","author":"Imtiaz","year":"2021","journal-title":"Subst Abuse Treat Prev Policy"},{"year":"2020","key":"2022041016280900400_CIT0042"},{"key":"2022041016280900400_CIT0043","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S1473-3099(20)30631-9","article-title":"SeroTracker: a global SARS-CoV-2 seroprevalence dashboard.","volume":"21","author":"Arora","year":"2021","journal-title":"Lancet Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/5\/ofac142\/43355421\/ofac142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/5\/ofac142\/43355421\/ofac142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T16:28:44Z","timestamp":1649608124000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac142\/6566041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,10]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac142","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,4,10]]},"article-number":"ofac142"}}